Merus

MA strategy deal block push come together form
Biotech

Genmab pays $8B to buy Merus and phase 3 bispecific

Genmab is continuing to build its pipeline of wholly owned cancer assets, this time paying $8 billion for Merus and its bispecific antibody.
James Waldron Sep 29, 2025 5:38am
race track

Bicara CEO: ASCO data resonate more with 'people that matter'

Jun 2, 2025 4:26pm
Blue race track

ASCO: Chasing Merus, Bicara shares 2-year HNSCC survival data

Jun 1, 2025 3:36pm
Businessman climbing steps to pluck a star from the sky

Merus hails 'unprecedented' survival on solid tumor bispecific

May 23, 2025 7:35am
An arrow incrementally going up stairs before pointing straight up Blue background

Merus touts cancer drug's strong profile with new data drop

Dec 2, 2024 11:59am
delay

FDA delays decision on Merus' first-in-class cancer drug

Nov 5, 2024 9:14am